Chairman of the Board
Mr. Kaufman served as Corporate Vice President of Applied Materials. Previously Mr. Kaufman was the founder and President of KLA Instruments Israel, and General Manager of Kulicke and Soffa Israel. Currently, he serves as chairman and director of several high-tech companies. Mr. Kaufman holds engineering degrees from the Technion – Israel Institute of Technology.
Mr. Gafni, B.Sc. MBA., is the founder and Chairman of Medoc Advanced Medical Systems Ltd. He has more than 20 years of experience in the medical device arena, previously holding positions in leading companies including Rafael and Iscar.
Mr. Shohet is the owner of ADY Consulting Group and serves as a strategic and business advisor. Prior to this role, Mr. Shohet was a Co-CEO of Netafim. Previous to this, Mr. Shohet served in various senior positions at Teva Pharmaceuticals Industries Ltd over a 24 year period, including Senior Vice President of Business Development, Chief Integration Officer and VP Central and Eastern Europe. Mr. Shohet holds a BA in economics from Bar-Ilan University.
Mr. Tabachnik served as the Executive Vice President and Chief Financial Officer of Oridion Systems, a successful patient monitoring company. He led their successful acquisition by the global healthcare company, Covidien, for $346 Million in 2012. Mr. Tabachnik later served as Covidien’s Director of Strategy and Portfolio EMEA. Previously Mr. Tabachnik has held a number of senior accounting positions in various distinguished firms in Israel and South Africa. Mr. Tabachnik is a Certified Public Accountant in Israel and holds a bachelor’s degree in accounting and economics from the Hebrew University of Jerusalem, Israel.
Mr. Weinstein is the Investment Manager at Benslie International Ltd. and a Director at Genomika Foundation. Mr. Weinstein has more than 10 years direct experience in the pharmaceutical industry holding key leadership positions. During his tenure, he has successfully executed transformational acquisitions, launched multiple products targeting physicians, and overseen greenfield start-ups. Mr. Weinstein holds an M.S. in Finance and an MBA from the Kellogg School of Management.
Mr. Weinstein has more than 8 years experience as executive and investor in the life sciences industry. He most recently served as Vice President of Innovation and Development at Abbott Laboratories. Prior to that he was Vice President of Strategy and Innovation at CFR Pharmaceuticals. He has a proven track record of launching over 300 products in the Pharmaceutical industry in Latin America and completing more than 20 licensing deals including Biotech products and Medical Devices.
He currently serves as a Board Member of Convexity Scientific, Via Surgical and Dog Parker. He previously was a board member of BMRC, a biotech research consortium in Chile.
Galit Zuckerman Stark
Ms. Zuckerman Stark brings to Medasense over fifteen years of entrepreneurship, management and engineering experience in both startups and large corporations. Ms. Zuckerman Stark founded Medasense upon discovering that while advanced algorithms are used frequently in many different industries such as semiconductors, communication, and many others, the discipline of medicine and specifically pain is still left behind.
Before founding Medasense she led a team of algorithm engineers at Applied Materials and worked at Nokia-Siemens and Nice Systems. She also served as a consultant for several start-up companies in the field of signal and image processing including BoneTone Communications which was successfully acquired by DSPG Inc in 2011.
Ms. Zuckerman Stark holds an M.Sc. degree in Electrical Engineering (cum laude, Engineering Faculty Excellence Program) and a B.Sc. in Computer Engineering (cum laude, Adi Lautman special program for outstanding students TAU) from Tel-Aviv University, Israel.
Dr. Shmuel Cabilly
Dr. Cabilly is an investor and a board member of several companies. Dr. Cabilly developed a new technology for recombinant antibody production during a post-doctoral fellow at Genentech. This invention was patented in world patents “The old Cabilly” and “The New Cabilly patent”. Today there are already 20 drugs in the market based on this technology among which are Herceptin, Rituxan, Traceba, Raptiva, Xolair and more. Dr. Cabilly was also a co-founder and a chief scientist of Ethrog Biotechnology where he invented major technologies in the field of chemistry.
Mr. Gavshon migrated to Australia from South Africa in 1978 where he was a partner in one of the largest law firms in that country. In Australia, initially he acted as Group General Counsel and Director of Corporate Affairs with worldwide responsibility for a multinational corporation based in Sydney.
Mr. Gavshon was a significant shareholder in, and served as an Executive Director of private and listed companies which developed icon brands.
He has gained broad business experience in Australasia, USA and Asia and has been involved in a number of successful equity ventures where he has also taken Board and advisory roles.
Mr. Gavshon is widely respected for the extensive community service he has given and occupied leading positions in the Australian not-for-profit sector. He holds commerce and law degrees from the University of Witwatersrand, South Africa.
Anne E. Sissel
Ms. Sissel is Vice President, Ventures as of July 2016 at Baxter International Inc. She is a CFA, holds BS, Finance from Indiana University Bloomington and MBA from the University of Pennsylvania – The Wharton School.
Ms. Sissel was on the founding team and executive team for Veracyte, Inc. (NASDAQ: VCYT). She led the finance and business development organization and was a cross-functional leader from early discovery through commercialization.
Prior to Veracyte, she worked in the Investment Banking Division of Goldman, Sachs & Co. in New York and San Francisco. Ms. Sissel has completed over $200bn in financing and M&A transactions for clients in the healthcare and technology industries.
Ms. Sissel was selected to Crain’s Chicago Top 50 in Tech List in 2015, Chicago Tribune Top Innovators 2016.
Ms. Sissel’s current Board and Observation roles include: Medasense, Opsonix, Inc., Sanifit S.L. and TVA Medical, Inc.
Mr. Vilenski (M.Sc.), is the former Chairman of Applied Materials Israel, former Executive Director of the Israel – US joint Bi-national Industrial Research and Development (BIRD) Foundation, former General Manager of KLA Instruments in Israel and former VP of Kulicke and Soffa (K&S). He was responsible for the successful integration in Israel of the independent subsidiaries for leading American high-tech companies: K&S, KLA Instruments, and Applied Materials. Dan currently serves on the Board of directors of several Israeli high-tech companies as well as on the boards of the Technion Institute and the Israeli National Nanotechnology Initiative.